Best Life Sciences Platforms and Tools Companies in Switzerland
The 176 best Life Sciences Platforms and Tools companies in Switzerland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Lunaphore.
Switzerland's Life Sciences Platforms and Tools sector is tracked here across 176 companies, ranked by disclosed equity funding and recent momentum — and the numbers tell a sharper story than you'd expect from a market this concentrated.
Total disclosed funding sits at $523M, with Lunaphore commanding the lion's share at $83M and Microcaps pulling $16M. That spread is wide: most of the 176 tracked companies are early-stage, and zero unicorns means the upside is still in front of us. The global market these companies feed into ran at roughly $89.4B in 2020 and is forecast to hit $183.8B by 2027, a 10.8% CAGR according to ResearchAndMarkets.com. Demand is being pulled by advances in quantitative accuracy and MS resolution, which is exactly the kind of technical edge Swiss platform builders tend to chase. Regulatory headwinds are real, but they tend to filter out weaker entrants faster than any market downturn would.
So what's worth watching right now? Venture Kick, MassChallenge and the EIC Fund are the most active backers in this cohort, which tells you the capital mix leans early and pan-European. If you're scanning this list for partnership or investment targets, the gap between Lunaphore's $83M and the next tier is the first thing to stress-test.
- Precedence Research
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Switzerland
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Lunaphore Developer of microfluidic-based instruments for tumor analysis | $83M | 38 mo ago | Acquired | 133 | 2014 | WordPressMySQLPHP+34 | — | 1 expansion |
| 2 | Xlife sciences Developer of drugs for multiple diseases | $63M | 66 mo ago | Public | — | 2013 | WebflowHighchartsGSAP+14 | — | — |
| 3 | NewBiologix Provider of engineered cell lines for drug development | $50M | 37 mo ago | Seed | — | 2022 | — | — | — |
| 4 | Araris Biotech Developer of novel antibody-drug conjugate linker technology | $41M | 38 mo ago | Acquired | 24 | 2019 | PHPApache HTTP ServerGoogle Font API+5 | 34 patents Patents concentrated in health & consumer products | — |
| 5 | InSphero Developer of cell based assays for drug screening | $35M | 38 mo ago | Series D | 63 | 2009 | WordPressMySQLPHP+30 | 81 patents 3D microfluidic organ‑on‑chip platforms for disease modeling and specimen vitrification. | 1 launch |
| 6 | NimbleGen NGS solutions for research applications | $31M | 227 mo ago | Acquired | 135 | 1999 | — | — | — |
| 7 | Nanolive Developer of label-free live cell imaging and analysis platforms and assays | $26M | 50 mo ago | Funding Raised | 73 | 2013 | — | 42 patents Label-free 3D optical diffraction tomography microscopy for cellular assay platforms | 4 job openings |
| 8 | 4-Antibody Antibody discovery and optimization platform for drug development | $21M | 233 mo ago | Acqui-Hired | 42 | 2002 | — | 8 patents Antibody and binding protein discovery/engineering using nucleic acid sequencing and modified lymphocytes | — |
| 9 | Microcaps Developer of microfluidic-based technology | $16M | 24 mo ago | Series A | 22 | 2018 | WordPressMySQLPHP+13 | 39 patents Microcaps produces microencapsulation systems for controlled-release hydrogel and solid matrix capsules. | 2 launchs |
| 10 | Creoptix Provider of web hosting, domain registration, and related support services | $15M | 80 mo ago | Acqui-Hired | 31 | 2009 | — | 42 patents Label-free biosensor platforms for high‑throughput kinetic analysis of biomolecular interactions | — |
| 11 | Andrew Alliance Provider of automated liquid handling tools and software for scientific labs | $14M | 88 mo ago | Acquired | 5 | 2011 | WordPressMySQLPHP+36 | 55 patents Automated liquid handling and lab robotics for microplate and pipette manipulation | — |
| 12 | Versameb Developer of therapies using proprietary technology platform for local delivery of therapeutic proteins | $13M | 71 mo ago | Seed | 16 | 2017 | — | 74 patents RNA‑based therapeutics and modulators of protein interactions and gene expression | — |
| 13 | Levitronix Manufacturer of motor-based process equipment | $12M | 202 mo ago | Funding Raised | — | 2001 | WordPressMySQLPHP+17 | 312 patents Patents concentrated in electrical & electronics | 4 job openings |
| 14 | QGel Hydrogel based cell culture system for drug discovery and drug-response assays | $12M | 114 mo ago | Series A | 15 | 2009 | — | 43 patents Hydrogel-based 3D cell culture platforms for organoid growth and drug screening | — |
| 15 | Biognosys Provider of proteomics service | $9M | 82 mo ago | Acquired | 71 | 2008 | Cart FunctionalityWooCommerceWordPress+35 | 35 patents Advanced DIA mass spectrometry data analysis and protein conformational/drug‑target kinetics | — |
| 16 | QUAD Systems Developer, manufacturer, integrator, and supplier of key components for NMR spectrometers | $8M | 53 mo ago | Series A | 6 | 2020 | — | — | — |
| 17 | arcoris bio Developer of nanotechnology reagents and protocols for RNA and protein detection | $8M | 7 mo ago | Seed | — | 2022 | — | — | — |
| 18 | Qnami Developer of quantum-based scanning probe microscopes | $7M | 61 mo ago | Series A | 27 | 2016 | WordPressMySQLPHP+25 | 20 patents Nanoscale magnetic field and temperature sensing for nanowire and nanomagnet devices. | — |
| 19 | Limula Developer of automated platform for cell and gene therapy manufacturing processes | $7M | 24 mo ago | Seed | 8 | 2020 | WordPressMySQLPHP+13 | 15 patents Automated bioreactor systems for manufacturing genetically engineered cell therapies | — |
| 20 | Rqmicro Developer of instruments, reagents, and kits for rapid pathogen detection | $6M | 62 mo ago | Series B | 14 | 2013 | — | 18 patents Patents concentrated in transport & manufacturing processes | — |
| 21 | Embion Technologies Developer of a synthetic biology platform for converting waste into useful chemicals for industrial uses | $5M | 54 mo ago | Series A | 13 | 2016 | — | — | — |
| 22 | MaxWell Biosystems Developer of an in vitro assay platform based on electrophysiology | $5M | 60 mo ago | Series A | 40 | 2016 | WordPressApple iCloud MailMicrosoft 365+36 | — | — |
| 23 | Histide Biotechnology startup developing novel therapeutics and cosmetics based on proprietary Cell Recoding platform | $5M | 139 mo ago | Series A | 14 | 2014 | — | 135 patents Therapeutic biologics for tissue regeneration and cancer cell reprogramming via growth-factor conjugates | — |
| 24 | SwissDeCode Provider of disposable DNA Kit for detection of food contaminants | $4M | 56 mo ago | Series A | 14 | 2016 | — | 6 patents Food safety certification and agricultural product testing systems | 1 partnership |
| 25 | CyanoGuard Developer of the next-generation cyanide monitoring device | $4M | 63 mo ago | Seed | 9 | 2016 | — | 20 patents Cyanide detection and quantification kits using optical analytical methods | — |
| 26 | PreComb Provides functional cancer profiling using biomarker analysis | $4M | 17 mo ago | Series A | 11 | 2018 | WordPressMySQLPHP+22 | — | — |
| 27 | InterAx Biotech Arrestin-based biosensors and computational methods for GPCR based drug discovery | $3M | 76 mo ago | Series A | 17 | 2016 | — | 12 patents Patents concentrated in chemistry & materials | — |
| 28 | Adaptyv Biosystems Provider of protein design, synthesis, testing, and validation services | $3M | 52 mo ago | Seed | 14 | 2021 | Webflow EcommerceWebflowKaTeX+16 | — | 1 job opening · 1 partnership |
| 29 | Stemergie Biotechnology Developing therapeutics targeting the metabolism of cancer stem cells | $2M | 172 mo ago | Series A | — | 2009 | — | 11 patents Mitochondrial Complex III inhibitors for therapeutic disease treatment | — |
| 30 | Nagi Bioscience Developer of a organism on a chip based technology | $2M | 78 mo ago | Seed | 10 | 2017 | — | 12 patents Microscopic imaging apparatus for nematodes and small biological specimens | — |
| 31 | AVA Biochem Developer of bio-based platform chemicals derived from renewable feedstocks | $2M | 61 mo ago | Funding Raised | — | 2014 | — | 14 patents Patents concentrated in chemistry & materials | — |
| 32 | SEED Biosciences Developer of programmable robotic liquid handling systems | $2M | 51 mo ago | Series A | 9 | 2018 | — | 4 patents Impedance-based biosensing platforms for analyzing biological cells and tissues | 1 partnership |
| 33 | Annaida Developer of sensor using magnetic resonance | $1M | 40 mo ago | Seed | 9 | 2018 | — | — | — |
| 34 | ORYL Photonics Developer of optical microscopes and light scattering devices for research | $953K | 11 mo ago | Series A | — | 2020 | — | — | 1 launch |
| 35 | SUN bioscience Provider of 3D cell culture systems for personalized medicine and organoid research | $664K | 55 mo ago | Funding Raised | — | 2015 | Cart FunctionalityWooCommerceWordPress+22 | — | — |
| 36 | 3Brain High resolution MicroElectrode Array (#MEA) platform to study #Brain and #retinal disorders ( #Alzheimer's… | $649K | 65 mo ago | Funding Raised | 34 | 2011 | Webflow EcommerceWebflowApple iCloud Mail+22 | 17 patents High‑throughput cellular assay platforms using probe array bio‑sensing technologies | — |
| 37 | Lascco Clinical-stage Biotech company developing technologies based on University/Academic research | $620K | 165 mo ago | Funding Raised | — | 2007 | — | 9 patents Peptide-based diagnostic assays for respiratory infections and IFN‑γ inhibitor therapies for motor neuron diseases | — |
| 38 | Epithelix Provider of 3D tissue and testing services for in-vitro drug testing for respiratory cells | $611K | 77 mo ago | Seed | — | 2006 | PHPGoogle MapsVimeo+11 | — | — |
| 39 | Nanosurf Provider of nano-microscopes for industrial and academic research | $607K | 102 mo ago | Acquired | 71 | 1997 | HubSpot CMS HubBootstrapEnvoy+16 | 24 patents Patents concentrated in computing, sensing & instrumentation | 1 award |
| 40 | Inofea Developing a nanoparticle platform technology to stabilize enzymes | $478K | 60 mo ago | Funding Raised | 9 | 2011 | — | 35 patents Enzymatic biocatalysis platforms for producing antibody‑drug and immunoligand conjugates | — |
| 41 | Lyncee Tec Developer of digital holographic microscopy for life science and industrial applications | $342K | 64 mo ago | Acquired | 16 | 2003 | — | — | — |
| 42 | TOFWERK Manufacturer of time of flight mass spectrometers for chemical analysis | $315K | 49 mo ago | Seed | 65 | 2002 | NginxSendgridMicrosoft 365+2 | 107 patents Advanced ion sources, ion‑molecule reactors, and mass‑analysis for semiconductor and battery diagnostics | — |
| 43 | Imina Developer of high precision micromanipulators for research | $256K | 112 mo ago | Seed | 17 | 2009 | October CMSPHPLaravel+16 | 4 patents Robotic electromechanical tool holder systems for mobile manipulators | 1 launch |
| 44 | Prometheus Life Technologies Developer of human tissue organoids for research purposes | $216K | 41 mo ago | Seed | 5 | 2022 | — | — | — |
| 45 | CEIDOS Provider of cell culturing devices for patients cells modification | $150K | 51 mo ago | Funding Raised | 8 | 2019 | — | 16 patents Real-time cell culture monitoring using dielectrophoretic analysis | — |
| 46 | Haelixa Developing DNA-based tracers to monitor temperature, light, pH, and oxidants for the energy industry | $128K | 4 mo ago | Acquired | 14 | 2015 | WordPress Block EditorWordPressMySQL+29 | 8 patents Anti-counterfeit marking and verification of products, especially pharmaceuticals. | 1 launch |
| 47 | BioCopy Developer of immunotherapies for tumor and autoimmune diseases | $116K | 92 mo ago | Funding Raised | 27 | 2018 | Node.jsReactNext.js App Router+9 | — | — |
| 48 | KYLYS Developer of technology to produce biomolecular reagents. | $112K | 37 mo ago | Seed | 4 | 2017 | — | — | — |
| 49 | Stratpharma Developing skin therapeutics using a patented polymer based drug delivery technology | $111K | 75 mo ago | Funding Raised | 113 | 2005 | WordPressMySQLSalesforce+28 | — | — |
| 50 | Amphasys Developer of label-free technology for pollen viability analysis | $109K | 72 mo ago | Funding Raised | 20 | 2012 | WordPressMySQLPHP+31 | 8 patents Pollen viability grading and milk cell‑load detection using optical/fluorescence analytical methods | — |
Top 12 Life Sciences Platforms and Tools companies in Switzerland
#1
Seed · Schlieren, Zurich · founded 2022$7.8Mraised▾
Developer of nanotechnology reagents and protocols for RNA and protein detection. The platform incorporates a nanotechnology-based signal amplification system. This system permits simultaneous multiplex target detection and is multimodal for applications like immunofluorescence and imaging mass cytometry. Designed for ease of use, it requires no specialized laboratory equipment. Scientific researchers in cell biology and genomics can perform accurate, high-throughput biomolecule quantification. This quantification complements other data analysis methods like RNA sequencing.
- Nov 2025Seed$7.8M
#2
Series A · Hombrechtikon, Zurich · founded 2018 · 11 employees$3.7Mraised▾
Provides functional cancer profiling using biomarker analysis. Its assay platform uses biomarkers and genetic profiles and provides information about the best possible proximation of the patient’s response from multiple therapeutic options. It helps a physician for choosing effective therapy for cancer treatment. Its offering is an analysis of biomarkers and genetic profiles for precision medicine.
- Dec 2024Series A—
- Oct 2022Seed$1.3M
- Apr 2021Seed$2.4M
#3
Acquired · Zurich, Zurich · founded 2015 · 14 employees$127.5Kraised▾
Haelixa provides intelligent DNA-based tracing solutions allowing fluid/item tracking and parameter monitoring (temperature, light, pH, oxidants) to support the energy industry (underground exploration and monitoring), and ensure product authentication and quality control as well as liability management. The tracers are composed of DNA sequences encapsulated within invisible particles that can be mixed with any fluid and item, providing it with a unique fingerprint, which is easily identified and quantified at parts per trillion level (1 milligram per ton) with bio-analytics used in medicine and forensics. The use of DNA permits to generate as many distinct fingerprints as are needed as unlimited DNA sequences are available. The encapsulation improves DNA stability, providing resilience in harsh conditions. Both DNA and particles can be engineered to obtain tracers capable of determining temperature, pH, oxidant concentration, light intensity. The main applications of the technology currently are - Reservoir Monitoring (characterize and monitor oil or geothermal reservoirs by tracking the movement of fluids in the subsurface) and Product Authentication (transparent identification a
- Feb 2026Seed$2.4M
- Sep 2019Seed—
- Sep 2017Grant (prize money)$730.2K
- 2017Seed$127.5K
#4
Acquired · Morges, Vaud · founded 2014 · 133 employees$82.7Mraised▾
Developer of microfluidic-based instruments for tumor analysis. The products include LabSat a tumor tissue staining device and COMET an automated staining and imaging platform that performs sequential immunofluorescence. The instruments are based on microfluidic staining technology called Fast Fluidic Exchange (FFEx).
- Mar 2023Series D$43.4M
- Mar 2023Venture Debt$10.8M
- Oct 2022Conventional Debt$9.9M
- Apr 2020Series C$2.1M
#5
Series A · Lausanne, Vaud · founded 2020$953.1Kraised▾
Developer of optical microscopes and light scattering devices for research. The company provides an ORYL screener, wide-field nonlinear microscope, and high-efficiency second-harmonic scattering system. These systems are uses for crystallization, aggregation, surface electrostatics, and surface chemistry in solution.
- Jul 2025Series A—
- Jan 2024Seed$953.1K
#6
Series A · Zurich, Zurich · founded 2018 · 22 employees$16.2Mraised▾
Microcaps develop microfluidic-based technology. Their technology enables to development of monodisperse capsules and emulsions of various sizes. The microparticles and microcapsules are used to protect active materials (in drug development). The monodisperse capsules are developed at industrial scale.
- Jun 2024Series A$10.4M
- Jan 2021Seed$5.6M
- Feb 2019Seed$130K
#7
Seed · Epalinges, Vaud · founded 2022$50Mraised▾
Provider of engineered cell lines for drug development. It offers DNA-based platform for the production of recombinant adeno-associated virus (rAAV) vectors, human and mammalian cell lines to produce advanced therapy medicinal products.
- May 2023Seed$50M
#8
Series D · Schlieren, Zurich · founded 2009 · 63 employees$35Mraised▾
Developer of cell-based assays for drug screening. The organotypic biological 3D microtissues and microtissue-based assays for biochemical compounds screening and predictive drug testing applications. It offers human prostate and mammary carcinoma, and rat liver microtissues. The company also provides compound toxicity testing, cell invasion assays, cell-to-cell interaction, cell-to-extracellular matrix interaction services. The company is focused on providing assays for metabolic diseases, oncology, and liver diseases.
- Mar 2023Series D—
- Jun 2020Grant (prize money)$56.2K
- Jan 2020Grant (prize money)$56.1K
- Jun 2018Series C$10M
#9
Acquired · Zurich, Zurich · founded 2019 · 24 employees$40.8Mraised▾
Developer of novel antibody-drug conjugate linker technology. It offers a proprietary peptide linker technology enabling efficient, site-specific payload attachment to antibodies. This results in homogenous, stable, and highly soluble antibody-drug conjugates (ADCs) with improved efficacy and reduced side effects. The technology simplifies manufacturing by using off-the-shelf antibodies, reducing development time and costs. The improved linker solubility minimizes aggregation, ensuring efficient binding to cancer cells. This approach offers a significant advancement in ADC development, leading to safer and more potent cancer therapies.
- Apr 2023Series A—
- Oct 2022Series A$24.3M
- Oct 2020Seed$14M
- Aug 2019Seed$2.6M
#10
Seed · La Tour de Peilz, Vaud · founded 2020 · 8 employees$6.8Mraised▾
Developer of automated platform for cell and gene therapy manufacturing processes. The platform combines a bioreactor and centrifuge into a single closed device. It supports various cell types, including T cells and hematopoietic stem cells. The technology aims to streamline manufacturing, reduce contamination risk, and enable scalability for commercial production.
- May 2024Seed$6.8M
- Nov 2022Grant (prize money)—
- Oct 2022Seed—
- Feb 2022Conventional Debt$108.1K
#11
Public · Zurich, Zurich · founded 2013$62.8Mraised▾
Developer of drugs for multiple diseases. The company is developing therapeutics for multiple indications such as antibody therapy for obesity, nanovesicles therapy for arthritis, antibody therapy for acute lymphocytic leukemia among others. The platform also offers services such as 3D bioprinting and AI-based software for cancer diagnosis among others.
- Dec 2020Series C$6.7M
- Nov 2019Series C$56.1M
#12
Funding Raised · Switzerland · founded 2013 · 73 employees$25.5Mraised▾
Developer of label-free live cell imaging and analysis platforms and assays. The company provides tools for holotomography and AI-driven live cell analysis. It offers platforms for long-term live cell imaging of single cells and cell populations. The company’s products support research in cytotoxicity, oncology, immuno-oncology, and cell metabolism. It also provides related accessories, training programs, and service contracts.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Switzerland
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 867 Switzerland-affiliated papers.
- ETH Zurich128
- SIB Swiss Institute of Bioinformatics94
- University of Zurich79
- University of Lausanne63
- University of Bern62
- Gene3→33
- Genome4→32
- Identification (biology)2→16
- Population1→12
- Sequence (biology)1→11
- Gene1→17
- Transcriptome2→11
- Genome2→7
- Proteome1→6
- Phylogenetic tree1→5
- Disease12
- Clinical trial10
- Computational biology7
- MEDLINE6
- Immune system5
Where bioinformatics is researched across Switzerland
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.